Lucentis (ranibizumab) - Roche, Novartis
Retraction Statement. (PubMed, Ophthalmic Res) - Oct 8, 2026 - "The authors' accepted manuscript "Comparative study of Curcumin and Lucentis on retinal neovascularization" [Ophthalmic Res...The authors did not clarify what data was available or provide this data within the given timeframe despite multiple attempts of contact.As a consequence of the authors' failure to respond to the journal about the original data for the study, the Editor has rescinded their original acceptance decision. Consequently, the published author's accepted manuscript has been retracted.The authors did not respond within the given timeframe to indicate agreement or disagreement with this decision." 
Journal • Age-related Macular Degeneration • Ophthalmology • GFAP
http://www.ncbi.nlm.nih.gov/pubmed/42839390
 
Oct 8, 2026
 
Prev Next